{"id":11645,"date":"2023-11-10T10:20:00","date_gmt":"2023-11-10T02:20:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11645"},"modified":"2024-11-07T10:25:07","modified_gmt":"2024-11-07T02:25:07","slug":"astrazeneca-reports-q3-2023-revenue-growth-and-oncology-milestones","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11645","title":{"rendered":"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones"},"content":{"rendered":"\n

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN<\/a>) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines, total revenues saw a growth of 13% YOY. For the first nine months of 2023, total revenues rose by 5% to USD 33.8 billion.<\/p>\n\n\n\n

Oncology Performance and Blockbuster Products<\/strong>
Oncology emerged as the strongest performer with a 20% YOY growth to USD 13.5 billion. This growth was driven by a 10% expansion for lung cancer therapy Tagrisso (osimertinib) to USD 4.38 billion, a 9% YOY increase for PARP inhibitor Lynparza (olaparib) to USD 2 billion, a 56% growth for PD-L1 Imfinfzi\/Imjudo (durvalumab) to USD 3.1 billion, and sales of the HER2-targeted antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) reaching USD 178 million. Other notable products included diabetes and heart failure therapy Farxiga (dapagliflozin) with USD 4.4 billion in sales, up 40% YOY, Soliris (eculizumab) with USD 2.4 billion, down -15% YOY, and Ultomiris (ravulizumab) with USD 2.1 billion in sales, up 58% YOY.<\/p>\n\n\n\n

China Market Dynamics and VBP Impact<\/strong>
China, AstraZeneca’s second-largest individual country market, saw a 1% growth in Q3 to USD 1.45 billion and a 5% YOY growth in the first nine months to USD 4.5 billion. Tagrisso sales were affected by price reductions due to National Reimbursement Drug List (NRDL) coverage, with the most recent price point effective from March 2023. A government anti-corruption campaign initiated in July 2023 led to market disruption and reduced promotional efforts, impacting sales. However, executives noted signs of recovery in Q4. David Fredrickson, EVP of AZ\u2019s Oncology Business, mentioned that Forxiga is the next drug set for China\u2019s volume-based program (VBP), with the earliest inclusion expected in round 10, forecasted for mid- to late-2024.<\/p>\n\n\n\n

Eccogene GLP-1 Licensing Deal and Anti-Obesity Strategy<\/strong>
AstraZeneca announced a potential USD 2 billion licensing deal with China-based biotech Eccogene, securing ex-China development rights to ECC5004, a once-daily, low-dose, oral GLP-1R agonist. Sharon Barr, EVP of BioPharmaceuticals R&D, highlighted ECC5004’s “best-in-class” profile, including greater tolerability, lower GI adverse event rates, and a simple manufacturing process. CEO Pascal Soriot emphasized plans to use ECC5004 for obesity and combination therapies for cardiovascular, renal, and metabolic diseases, positioning AstraZeneca as a major player in the global obesity market.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,39,27,871,86,82],"class_list":["post-11645","post","type-post","status-publish","format-standard","hentry","category-company","tag-astrazeneca","tag-az","tag-diabetes","tag-finanical-reports","tag-nasdaq-azn","tag-obesity","tag-vbp-voluem-based-procurement"],"yoast_head":"\nAstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines, total revenues saw a growth of 13% YOY. For the first nine months of 2023, total revenues rose by 5% to USD 33.8 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11645\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11645\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-10T02:20:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-07T02:25:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11645#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11645\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones\",\"datePublished\":\"2023-11-10T02:20:00+00:00\",\"dateModified\":\"2024-11-07T02:25:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11645\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"Diabetes\",\"Finanical Reports\",\"NASDAQ: AZN\",\"Obesity\",\"VBP (voluem-based procurement)\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11645#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11645\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11645\",\"name\":\"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-10T02:20:00+00:00\",\"dateModified\":\"2024-11-07T02:25:07+00:00\",\"description\":\"UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines, total revenues saw a growth of 13% YOY. For the first nine months of 2023, total revenues rose by 5% to USD 33.8 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11645#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11645\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11645#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones - Insight, China's Pharmaceutical Industry","description":"UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines, total revenues saw a growth of 13% YOY. For the first nine months of 2023, total revenues rose by 5% to USD 33.8 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11645","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11645","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-10T02:20:00+00:00","article_modified_time":"2024-11-07T02:25:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11645#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11645"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones","datePublished":"2023-11-10T02:20:00+00:00","dateModified":"2024-11-07T02:25:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11645"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","Diabetes","Finanical Reports","NASDAQ: AZN","Obesity","VBP (voluem-based procurement)"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11645#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11645","url":"https:\/\/flcube.com\/?p=11645","name":"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-10T02:20:00+00:00","dateModified":"2024-11-07T02:25:07+00:00","description":"UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines, total revenues saw a growth of 13% YOY. For the first nine months of 2023, total revenues rose by 5% to USD 33.8 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11645#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11645"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11645#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11645"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11645\/revisions"}],"predecessor-version":[{"id":11646,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11645\/revisions\/11646"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}